Iveric Bio is an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs.
Our strategy is focused on developing multiple, complementary assets to treat a broad spectrum of retinal diseases. We intend to do this by potentially studying Zimura in indications beyond geographic atropy secondary to dry AMD and autosomal recessive Stargardt disease and by advancing the development of IC-500 our HtrA1 inhibitor.
Having both Zimura and IC-500 in our pipeline positions us to potentially provide treatments for patients with various types and stages of AMD, the leading cause of vision loss in the elderly. We are also developing novel gene therapy technology to treat orphan inherited retinal diseases (IRDs). IRDs can be caused by many different mutations of a single gene. Our strategy is to develop mutation independent treatment options to potentially treat the entire group of patients with a particular IRD.